Ir para o conteúdo principal

ImpediMed (ASX: IPD) — Perfil da empresa, notícias e dados financeiros

Logo de ImpediMed
IPD ImpediMed
ImpediMed primary media
Perfil da empresa

ImpediMed

ImpediMed is a medical technology company that develops and commercializes non-invasive bioimpedance spectroscopy devices for fluid status and body composition monitoring. The company's core product, the SOZO Digital Health Platform, utilizes bioimpedance spectroscopy by taking measurements across 256 frequencies to differentiate intra- and extracellular fluid levels. Its application suite includes L-Dex analysis for early lymphedema detection, HF-Dex for heart failure fluid assessment, BodyComp for tissue composition analysis, and sarcopenia risk screening. ImpediMed serves clinical markets across cancer survivorship, heart health management, medical weight management, and wellness research.

Resumo

Public AUParticipação acionária
1999Ano de fundação
51–200Funcionários
Carlsbad, United StatesSede
Carregando mapa...
Presença global

Operações

Produtos e/ou serviços de ImpediMed

  • SOZO Digital Health Platform: Non-invasive bioimpedance spectroscopy system measuring 256 frequencies in a single rapid scan to separate intra- and extracellular fluid, delivering actionable patient data across cloud-connected clinical workflows at point of care.
  • L-Dex Analysis for Lymphedema: FDA-cleared diagnostic application evaluating subclinical fluid accumulation to support early intervention, preventing the progression of secondary lymphedema in oncology patients, including breast cancer survivors undergoing treatment or surveillance.
  • BodyComp and Segmental BodyComp Analysis: Whole-body and segmental assessment solutions measuring fluid distribution, skeletal muscle, and fat mass to monitor patient health responses during medical weight management, GLP-1 therapy, and wellness programs.
  • HF-Dex Analysis for Heart Failure: Specialized fluid monitoring application providing real-time measurements of fluid accumulation to assist clinicians in tracking disease progression, optimizing diuretic therapy, and improving outpatient management of heart failure patients.
  • Sarcopenia Risk Assessment: Clinical evaluation feature on the digital health platform that non-invasively analyzes muscle mass and tissue composition to identify sarcopenia risk across oncology, geriatric, and chronic illness care continuum.
  • Lymphedema Prevention Program: Structured clinical program combining bioimpedance spectroscopy technology, evidence-based protocol guidelines, and patient education resources to implement routine lymphedema surveillance in oncology and survivorship care programs.

equipe executiva do ImpediMed

  • Erik AndersonCEO, MD & Director
  • McGregor GrantCFO & Executive Director
  • Julie KuhlkenSenior Director of Marketing
  • Erik JohnsonHead of Sales
  • Ashley MunozDirector of Human Resources
  • Gina KimballHead of Commercial Operations
  • Leanne RalphCompany Secretary

Comunicados recentes

O que a ImpediMed (IPD) comunicou ao mercado, do mais recente para o mais antigo.

  1. 2026 AGM - Results of Meeting
  2. 2026 AGM - CEO's Presentation
  3. 2026 AGM - Chair's Address
  4. Investor Presentation
  5. Quarterly Activities Report and Appendix 4C - Sep-2026 QtrFato relevante
  6. Change of Director's Interest Notice - Mr Andrew Grant
  7. Change of Director's Interest Notice - Ms Emmanuel-Donnelly
  8. Change of Director's Interest Notice - Ms Janelle Delaney

Principais indicadores financeiros

Resultados divulgados pela ImpediMed, em AUD.

Cap. de mercado
18,3 mi
Receita (TTM)
14,6 mi
P/L
—
LPA (diluído, TTM)
-0.0
Dividend yield
—
Margem de lucro
-170.4%
Receita e lucro anuais da ImpediMed
Fim do ano fiscalReceitaResultado operacionalLucro líquido
14,6 mi-22,1 mi-24,9 mi
12,7 mi-24,2 mi-23,2 mi
10,3 mi-19 mi-19,8 mi
11,3 mi-22,8 mi-20,5 mi